Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan

摘要: Background and Aim Biliary tract carcinomas (BTCs) are difficult to diagnose treat. Epidermal growth factor receptor (EGFR) represents a therapeutic target for the BTCs. Mutations of EGFR gene activation its downstream pathways, including KRAS BRAF, predict sensitivity anti-EGFR treatment. The aims this study were analyze EGFR, BRAF mutations in BTCs their association with clinical outcomes. Methods Paraffin-embedded specimens containing 137 resected at National Taiwan University Hospital between 1995 2004 analyzed. exons 18–21 gene, codon 12, 13 61 V600E mutation We examined correlation these overall survival, tumor location, stage, differentiation BTCs. Results Thirteen (9.5%) BTC patients had while 23 (16.8%) mutations. Only one patient mutation. Factors influencing survival on univariate analysis differentiation, On multivariate analysis, stage independent prognostic factors. A or prognosis was not observed. Conclusions EGFR uncommon is rare an marker addition differentiation. No simultaneous extrahepatic cholangiocarcinoma gallbladder carcinoma found. should be evaluated when tailoring molecular-targeted therapy